For example, quadruple gene-engineered CAR-iNK cells were designed for dual targeting against multiple myeloma (MM) through the introduction of specific CAR for B cell maturation antigen (BCMA) and high-affinity non-cleavable CD16 to augment ADCC activity. This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.